COMPANY OVERVIEW
Recursion Pharmaceuticals (NASDAQ: RXRX), headquartered in Salt Lake City, Utah, is a clinical-stage biotechnology company industrializing drug discovery using AI and machine learning. With one of the world's largest proprietary biological datasets (36+ petabytes) and strategic partnerships with Nvidia, Bayer, and Roche/Genentech, Recursion is pioneering computational approaches to decode biology and identify new therapeutics.
PLATFORM CAPABILITIES
- Phenomics: High-content cellular imaging generating 2.2M experiments weekly
- Foundation Models: Nvidia partnership for biological AI/ML foundation models (BioNeMo)
- Cyclica Acquisition: Proteome-wide drug interaction prediction (MatchMaker platform)
- Valence Acquisition: Generative chemistry for de novo molecule design
- Tempus Labs: Clinical data partnership for real-world evidence
PIPELINE & PARTNERSHIPS
- Clinical Programs: REC-994 (cerebral cavernous malformation), REC-4881 (FAP), REC-3964 (C. diff)
- Roche/Genentech: $150M+ deal for neuroscience and oncology targets
- Bayer Partnership: Up to $1B for fibrotic disease programs
- Nvidia BioNeMo: Co-development of biological foundation models
DATA SCALE
Recursion operates one of the world's largest automated biology laboratories, generating cellular images across thousands of disease models and genetic perturbations. Their Recursion OS platform integrates phenomics, transcriptomics, and chemistry data to map biological relationships at unprecedented scale—enabling drug discovery in weeks rather than years.